Epigenetic instability is rare in fibrolamellar carcinomas but common in viral-associated hepatocellular carcinomas

Modern Pathology

Volumn 21, Issue 6, 2008, Pages 670-675

  Vivekanandan, Perumal ^a   Torbenson, Michael ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Fibrolamellar carcinoma; Hepatocellular carcinoma; HPP1; Methylation; RASSF1A; Viral hepatitis

Indexed keywords

CATENIN CADHERIN ASSOCIATED PROTEIN BETA 1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; GLUTATHIONE TRANSFERASE P1; PROTEIN HPP1; PROTEIN P16; PROTEIN P53; PROTEIN RARA; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; SUPPRESSOR OF CYTOKINE SIGNALING 1; TUMOR SUPPRESSOR PROTEIN; UVOMORULIN;

ADULT; ARTICLE; CLINICAL ARTICLE; EPIGENETICS; FEMALE; FIBROLAMELLAR CARCINOMA; GENE MUTATION; HUMAN; HUMAN TISSUE; LAMELLAR BODY; LIVER CELL CARCINOMA; LIVER DISEASE; MALE; METASTASIS; METHYLATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ADULT; CARCINOMA, HEPATOCELLULAR; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENES, TUMOR SUPPRESSOR; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; PROMOTER REGIONS (GENETICS);

EID: 44349154093     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2008.32     Document Type: Article

References (33)

1. Kakar S, Burgart LJ, Batts KP, et al. Clinicopathologic features and survival in fibrolamellar carcinoma: comparison with conventional hepatocellular carcinoma with and without cirrhosis. Mod Pathol 2005;18:1417-1423.
2. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006;6:674-687.
3. Herath NI, Leggett BA, MacDonald GA. Review of genetic and epigenetic alterations in hepatocarcinogenesis. J Gastroenterol Hepatol 2006;21:15-21.
4. Marchio A, Pineau P, Meddeb M, et al. Distinct chromosomal abnormality pattern in primary liver cancer of non-B, non-C patients. Oncogene 2000;19:3733-3738.
5. Terracciano LM, Tornillo L, Avoledo P, et al. Fibrolamellar hepatocellular carcinoma occurring 5 years after hepatocellular adenoma in a 14-year-old girl: a case report with comparative genomic hybridization analysis. Arch Pathol Lab Med 2004;128:222-226.
6. Wilkens L, Bredt M, Flemming P, et al. Cytogenetic aberrations in primary and recurrent fibrolamellar hepatocellular carcinoma detected by comparative genomic hybridization. Am J Clin Pathol 2000;114:867-874.
7. Kannangai R, Wang J, Liu QZ, et al. Survivin overexpression in hepatocellular carcinoma is associated with p53 dysregulation. Int J Gastrointest Cancer 2005;35:53-60.
8. Honda K, Sbisa E, Tullo A, et al. p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation. Br J Cancer 1998;77:776-782.
9. Terris B, Pineau P, Bregeaud L, et al. Close correlation between beta-catenin gene alterations and nuclear accumulation of the protein in human hepatocellular carcinomas. Oncogene 1999;18:6583-6588.
10. Kannangai R, Vivekanandan P, Martinez-Murillo F, et al. Fibrolamellar carcinomas show over expression of genes in the RAS, MAPK, PIK3, and xenobiotic degradation pathways. Hum Pathol 2007;38:639-644.
11. Park HJ, Yu E, Shim YH. DNA methyltransferase expression and DNA hypermethylation in human hepatocellular carcinoma. Cancer Lett 2006;233:271-278.
12. Yu J, Zhang H, Gu J, et al. Methylation profiles of thirty four promoter-CpG islands and concordant methylation behaviours of sixteen genes that may contribute to carcinogenesis of astrocytoma. BMC Cancer 2004;4:65.
13. Yu J, Ni M, Xu J, et al. Methylation profiling of twenty promoter-CpG islands of genes which may contribute to hepatocellular carcinogenesis. BMC Cancer 2002;2:29.
14. Fukushima N, Sato N, Sahin F, et al. Aberrant methylation of suppressor of cytokine signalling-1 (SOCS-1) gene in pancreatic ductal neoplasms. Br J Cancer 2003;89:338-343.
15. Katoh H, Shibata T, Kokubu A, et al. Epigenetic instability and chromosomal instability in hepatocellular carcinoma. Am J Pathol 2006;168:1375-1384.
16. Chim CS, Wong SY, Pang A, et al. Aberrant promoter methylation of the retinoic acid receptor alpha gene in acute promyelocytic leukemia. Leukemia 2005;19:2241-2246.
17. Sato F, Shibata D, Harpaz N, et al. Aberrant methylation of the HPP1 gene in ulcerative colitis-associated colorectal carcinoma. Cancer Res 2002;62:6820-6822.
18. Ueki T, Toyota M, Sohn T, et al. Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res 2000;60:1835-1839.
19. Lee JO, Kwun HJ, Jung JK, et al. Hepatitis B virus X protein represses E-cadherin expression via activation of DNA methyltransferase 1. Oncogene 2005;24:6617-6625.
20. Calvisi DF, Ladu S, Gorden A, et al. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 2006;130:1117-1128.
21. Agathanggelou A, Cooper WN, Latif F. Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Res 2005;65:3497-3508.
22. Zhang YJ, Ahsan H, Chen Y, et al. High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma. Mol Carcinog 2002;35:85-92.
23. Zhong S, Yeo W, Tang MW, et al. Intensive hypermethylation of the CpG island of Ras association domain family 1A in hepatitis B virus-associated hepatocellular carcinomas. Clin Cancer Res 2003;9:3376-3382.
24. Sugawara W, Haruta M, Sasaki F, et al. Promoter hypermethylation of the RASSF1A gene predicts the poor outcome of patients with hepatoblastoma. Pediatr Blood Cancer 2006;49:240-249.
25. Di Gioia S, Bianchi P, Destro A, et al. Quantitative evaluation of RASSF1A methylation in the non-lesional, regenerative and neoplastic liver. BMC Cancer 2006;6:89.
26. Hamilton JP, Sato F, Greenwald BD, et al. Promoter methylation and response to chemotherapy and radiation in esophageal cancer. Clin Gastroenterol Hepatol 2006;4:701-708.
27. Brucher BL, Geddert H, Langner C, et al. Hypermethylation of hMLH1, HPP1, p14(ARF), p16(INK4A) and APC in primary adenocarcinomas of the small bowel. Int J Cancer 2006;119:1298-1302.
28. Ebert MP, Mooney SH, Tonnes-Priddy L, et al. Hypermethylation of the TPEF/HPP1 gene in primary and metastatic colorectal cancers. Neoplasia 2005;7:771-778.
29. Suzuki M, Shigematsu H, Shames DS, et al. DNA methylation- associated inactivation of TGFbeta-related genes DRM/Gremlin, RUNX3, and HPP1 in human cancers. Br J Cancer 2005;93:1029-1037.
30. Shibata DM, Sato F, Mori Y, et al. Hypermethylation of HPP1 is associated with hMLH1 hypermethylation in gastric adenocarcinomas. Cancer Res 2002;62:5637-5640.
31. Young J, Biden KG, Simms LA, et al. HPP1: a transmembrane protein-encoding gene commonly methylated in colorectal polyps and cancers. Proc Natl Acad Sci USA 2001;98:265-270.
32. Waki T, Tamura G, Sato M, et al. Age-related methylation of tumor suppressor and tumor-related genes: an analysis of autopsy samples. Oncogene 2003;22:4128-4133.
33. Roberts LR, Gores GJ. Emerging drugs for hepatocellular carcinoma. Expert Opin Emerg Drugs 2006;11:469-487.